Agoracom Blog Home

Posts Tagged ‘CSE’

#Palladium Weekly: Uptrend Set To Prevail This Year – SPONSOR: New Age Metals $NAM.ca $WG.ca $XTM.ca $WM.ca $PDL.ca $GLEN #PGM

Posted by AGORACOM-JC at 5:27 PM on Tuesday, April 28th, 2020

SPONSOR: New Age Metals Inc. The company owns one of North America’s largest primary platinum group metals deposits in Sudbury, Canada. The company has an updated NI 43-101 Mineral Resource Estimate of 2,867,000 PdEq Measured and Indicated Ounces, with an additional 1,059,000 PdEq Ounces Inferred. Learn More.

Palladium Weekly: Uptrend Set To Prevail This Year

  • We continue to believe that palladium benefits from the tightest fundamental backdrop, with the market likely to post a meaningful deficit in 2020 despite a contraction in automotive demand.
  • The negative seasonality in May-June could lead to some palladium price weakness, which we would view as a buying opportunity.

Thesis

Welcome to Orchid’s Palladium Weekly report, in which we discuss palladium prices through the lenses of the Aberdeen Standard Physical Palladium Shares ETF (PALL).

PALL has come under downward pressure since the start of April, despite a strong performance across the rest of the precious metals space.

The recent underperformance of palladium is driven by three main factors:

  1. Less exposure to South African PGM production disruptions
  2. More sensitivity to the recession in the automotive sector
  3. Less safe-haven demand

However, we continue to believe that palladium benefits from the tightest fundamental backdrop, with the market likely to post a meaningful deficit in 2020 despite a contraction in automotive demand for PGMs.

As a result, we expect the uptrend in PALL to prevail this year and next.

For Q2, we see PALL trading between $170 and $285 per share, implying a risk/reward skewed to the upside.

Source: Trading View, Orchid Research

About PALL

For investors seeking exposure to the fluctuations of palladium prices, PALL is an interesting investment vehicle because it seeks to track spot palladium prices by physically holding palladium bars, which are located in JPM vaults in London and Zurich. The vaults are inspected twice a year, including once randomly.

The Fund summary is as follows:

PALL seeks to reflect the performance of the price of physical palladium, less the Trust’s expenses.

Its expense ratio is 0.60%. In other words, a long position in PALL of $10,000 held over 12 months would cost the investor $60.

Liquidity conditions are poorer than that for platinum. PALL shows an average daily volume of $3 million and an average spread (over the past two months) of 0.33%.

Speculative positioning

Source: CFTC, Orchid Research

The speculative community slashed by the equivalent of ~2 koz its net long position in NYMEX palladium in the week to April 21, according to the CFTC. The NYMEX palladium price sold off by 6.3% over the corresponding period, suggesting the presence of additional selling pressure stemming from the OTC market and the physical market.

Since the start of the year, the speculative community has sold the equivalent of 1.053 moz of net long positions in NYMEX palladium, representing around 15% of annual supply. Despite this, the NYMEX palladium price is still up nearly 6% YTD. This highlights the fundamental strength in the physical market.

Because palladium’s spec positioning is very light (the net spec length is at just 10% of open interest), there is plenty of room for speculative buying pressure in case of a positive swing in sentiment among the speculative community.

Implications for PALL: The current spec positioning in NYMEX palladium is a potential bullish force for palladium prices due to the ample dry powder available to deploy among the speculative community. A renewed wave of spec buying in NYMEX palladium would push the NYMEX palladium price much higher, thereby boosting PALL in the process.

Investment positioning

Source: Orchid Research

ETF investors bought around 3 koz of palladium in the week to April 24, marking the 2nd week of net buying.

Given the weakness in automotive demand for palladium due to the COVID-19 crisis, the re-emergence of palladium ETF buying could help underpin the uptrend in the NYMEX palladium price. That said, we contend that it is too early to assert that a sustained positive change in investor sentiment toward palladium has occurred this month.

ETF investors have sold roughly 193 koz since the start of the year, marking a 28% decline in palladium ETF holdings.

Once again, despite the contraction in ETF demand for palladium, the NYMEX palladium price is up on the year. This shows the extent to which the physical palladium market is tight.

Implications for PALL: A resumption of ETF inflows in palladium would be bullish for the NYMEX palladium price and thus PALL.

Automotive demand

Last week, we discussed the supply side of the palladium market. This week, we discuss the outlook for automotive demand for palladium.

Source: Johnson Matthey

Palladium demand from the automotive industry represents around 85% of gross palladium demand, according to Johnson Matthey.

JP Morgan predicts a contraction of 13% in global light vehicle production this year, including a contraction of 25% YoY in the first quarter. In Q1, JP Morgan estimates that Chinese production contracted by 50% YoY while production dropped by 17% YoY both in North America and Europe.

This would translate into a decline of roughly 7% in automotive demand for palladium this year.

Source: JPM

Implications for PALL: The contraction in automotive demand for palladium should be largely offset by the contraction in palladium mine supply in 2020. As such, the palladium market is likely to remain in a meaningful deficit this year and post an even deeper deficit next year. As the fundamental tightness in the physical palladium market is set to prevail, we believe that the uptrend in PALL is intact for this year and next.

Closing thoughts

We expect the uptrend in PALL to prevail in 2020 and next year, principally because the palladium market is expected to post a meaningful deficit in spite of the recession in the automotive industry.

The extremely low level of visible inventories is likely to intensify the positive impact on palladium prices.

Given the negative seasonality in May-June, we stand ready to buy the dips in case of a retest of the recent lows.

For Q2, we see PALL trading between $170 and $285 per share, implying a risk/reward skewed to the upside.

Source: https://seekingalpha.com/article/4340578-palladium-weekly-uptrend-set-to-prevail-this-year

Else Nutrition $BABY.ca Announces Filing of Preliminary Base Shelf Prospectus $MAT $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 12:25 PM on Tuesday, April 28th, 2020
  • Filed its preliminary base shelf prospectus
  • Filing of the Shelf Prospectus, when made final, will allow the Company to qualify the distribution by way of prospectus in British Columbia, Alberta and Ontario of up to C$20,000,000 of common shares, warrants to purchase common shares, units, or any combination thereof, during the 25-month period that the Shelf Prospectus is effective

Not for Distribution in the U.S. or to U.S. Newswire Services

VANCOUVER, BC / April 28, 2020 / Else Nutrition Holdings Inc. (the “Company” or “Else Nutrition” or “Else“) (TSXV:BABY) (OTCQB:BABYF) is pleased to announce that today it has filed its preliminary base shelf prospectus (the “Shelf Prospectus“) with the British Columbia Securities Commission, the Alberta Securities Commission and the Ontario Securities Commission. A copy of the Shelf Prospectus can be found on the Company’s SEDAR profile at www.sedar.com.

The filing of the Shelf Prospectus, when made final, will allow the Company to qualify the distribution by way of prospectus in British Columbia, Alberta and Ontario of up to C$20,000,000 of common shares, warrants to purchase common shares, units, or any combination thereof, during the 25-month period that the Shelf Prospectus is effective. Should the Company decide to offer securities during this period, the specific terms, including the use of proceeds from any offering, will be set forth in a related prospectus supplement to the Shelf Prospectus, which will be filed with the applicable securities commissions.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the qualification under the securities laws of any such jurisdiction.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition GH Ltd. (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc., is a publicly-traded company, listed on the TSX Venture Exchange under the trading symbol “BABY” and is quoted on the US OTC Markets QB board under the trading symbol “BABYF”. The Company’s Executive and Advisory Board includes leaders hailing from Abbott Nutrition, Mead Johnson, Boston Children’s Hospital, ESPHGAN (European Society for Pediatric Gastroenterology, Hepatology and Nutrition), Plum Organics, Tel Aviv University’s Sackler Faculty of Medicine, and Gastroenterology & Nutrition Institute of RAMBAM Medical Center.

For further information, please contact:

Ms. Hamutal Yitzhak, CEO of Else Nutrition
Email: [email protected]

Mr. Sokhie Puar, Director of Else Nutrition
Telephone: 604-603-7787
Email: [email protected]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities described herein have not been registered under the U.S. Securities Act or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the U.S. Securities Act and any applicable state securities laws.

Certain information contained herein constitutes “forward-looking information” under Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the Shelf Prospectus. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “will” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including: the receipt of all necessary regulatory approvals, use of proceeds from the financing, capital expenditures and other costs, and financing and additional capital requirements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward looking information. The Company will not update any forward-looking statements or forward-looking information that is incorporated by reference herein, except as required by applicable securities laws.

MUST WATCH INTERVIEW OF THE YEAR – Empower Clinics $CBDT.ca Closes Up 77% On 25M Shares. This Is Why … And This Is Where It Is Going $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 9:47 PM on Monday, April 27th, 2020

With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would kill for.  Patient visits increased 800% in February. 590% in March and 480% for Q1. 

More importantly, it is the only small cap company on the continent (that we know of) that is capable of launching COVID-19 Antibody Testing for individuals and businesses nationwide.  Why?  Because its simply not enough to be able to get your hands on some test kits.  The real challenge is having the infrastructure in place to test people in clinics, via drive though and in the workplace.    

It’s pretty much a military precision process that few small cap CEO’s could handle.  

But Empower Clinics CEO, Steven McAuley, is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth.  

And now he’s set his sights on Antibody Testing.  He’s not just looking, he’s already started.  

Forget NetFlix Tonight.  Watch this.

VIDEO: Else Nutrition $BABY.ca Has $10M In Cash And A Billion Dollar Shareholder To Launch Plant Based Toddler Foods Around The World $MAT $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 6:04 PM on Monday, April 27th, 2020

When the subsidiary of a Billion Dollar, Nutrition Focused company buys 11.5% of your stock, agrees to a voluntary 12-month lock up and holds anti-dilution rights to maintain it’s ownership percentage by buying a proportionate number of shares in any future financing, it is safe to assume you have a strategic investor who believes in the future of your company.    When that same strategic investor wants to then help your company expand into large international markets, it is safe to assume your plant based food capabilities are amongst the most respected in the world.   This is just a glimpse into the strength of Else Nutrition (BABY:TSXV) (BABYF:OTCQB), an Israeli based, award winning plant based food nutrition company that is giving small cap investors an opportunity to participate in the global paradigm shift towards plant-based, clean label foods.   BUT THERE IS MORE

  • Else has a $10,000,000 war chest for a US product launch in Q2 and to start signing international agreements in Q3. 
  • These global plans are supported by patents in 22 countries, with another 44 countries pending.  
  • Else developed the world’s first 100% plant based, non-dairy, non-soy baby formula

Given all of these achievements, it should come as no surprise that Else Nutrition is made up of Executives & Advisors from globally renowned companies and institutions.   If you believe in the future of plant-based, clean label foods or want to discover its possibilities, then watch our first ever interview with Hamutal Yitzhak, the CEO and Co-Founder of Else Nutrition who will tell you about both the Company’s origins and future path.

Mota Ventures $MOTA.ca to Replicate Successful U.S. Business Model for European Expansion of CBD Products, Immune Product Line and CBD Hand Sanitizer $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 5:42 PM on Monday, April 27th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / April 27, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC:PEMTF) (the “Company“) is pleased to announce that it will be replicating its highly successful business plan and operations in the United States for expansion into the European market with its Sativida brand, acquired on March 26, 2020. Sativida is already one of the top search-ranked online retailers of CBD products in Spain and Mexico, with distribution channels in Spain, Portugal, Austria, Germany, France and the United Kingdom.

SUCCESSFUL USA BUSINESS MODEL EXPECTED TO SIGNIFICANTLY BOOST EUROPEAN OPERATIONS

Year-to-Date in 2020, Mota Ventures has announced the following significant milestones from its U.S. operations:

  • Interim Record Of 14,388 New Customers For April 1 – 23.
  • Record Of 20,959 New Customers For The Month Of March
  • Revenue Of $4,290,000 In March
  • Revenue Of $2,981,000 In February, Representing Growth Of 832% over same period last year

With the Company’s e-commerce capabilities and success in the U.S. market, combined with the current search engine strength and distribution channels of the Sativida brand, management is very confident in its prospects for rapid customer acquisition throughout Europe. This confidence is further supported by the Company’s successful launch of its immune support product line, as well as, the May 1 launch of its CBD based hand sanitizer, both of which will be included in the European expansion.

Much of the Company’s success in the U.S. market has been attributed to its’ strong supply chain, which has continued to operate uninterrupted despite global turmoil in 2020. The Company has been actively sourcing multiple CBD suppliers in Europe to ensure a supply chain that is as strong and consistent as the North America operations. The Company will be announcing further details of the European expansion in the coming weeks as they become available.

“We are excited to announce this European expansion plan. As the world economy begins to awaken, now is the opportune to utilize what we have accomplished in the United States and implement the same strategies in Europe. There are several key market opportunities we have identified in Europe and now is the time to capitalize. I look forward to announcing an official launch date in the coming weeks” stated Ryan Hoggan, CEO of the Company.

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the U.S. through its Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

About Sativida

Sativida is a producer and online retailer of CBD and branded CBD products in various jurisdictions in Europe, including Spain and the United Kingdom. Sativida currently develops and retails a vast range of organic CBD oils and cosmetics across Europe and is currently expanding its distribution network internationally.

This News Release is available on the company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan

Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

How to spot “fake news” and misinformation in the era of #COVID19 – SPONSOR: Datametrex AI Limited $DM.ca

Posted by AGORACOM-JC at 5:06 PM on Monday, April 27th, 2020

SPONSOR: Datametrex AI Limited (TSX-V: DM) A revenue generating small cap A.I. company that NATO and Canadian Defence are using to fight fake news & social media threats. The company is working with US Government agencies on Covid19 and Coronavirus fake news and disinformation. The company also obtained the rights to import and sell COVID-19 test kits from South Korea – Click here for more info.

How to spot “fake news” and misinformation in the era of COVID-19

  • COVID-19’s arrival in Canada has brought many side-effects, including growing concerns about misinformation and deliberately dishonest media dubbed “fake news”.
  • Although automatic-detection systems have been tested, the rise of misinformation appears to be inherently linked to social media.

By: Justin Madu

However, less-than-factual sources generally share a few warning signs.

One of the biggest red flags that something isn’t right is a headline that makes bold or outlandish claims:

“If it seems like clickbait, don’t click on it because chances are it is not going to be legitimate or scientifically-proven information. If it is a sensational blurb, that is probably a good sign not to click on the article and believe everything inside,” explained Wendy Gray, Vista Radio’s National News Director.

Some copycats might even mimic trusted news sources.

“Some stories look like they’re coming from legitimate media outlets but there will be slight alterations to the URL,” said Gray

Similarly, misinformation may be spread through untrustworthy websites claiming to be news outlets. If you’re not familiar with a website, extra skepticism may be required.

Gray added the social climate of a global pandemic can lead to the spread of less-than-scientific data.

Looking at an article’s sources remains important, as medical doctors and public health officials remain the best source for reliable information.

The public should be cautious as many people earn doctorates, alongside the title of “Dr.”, without any medical training.

“You always go with what the medical experts are saying,” Gray stated, adding “politicians are not medical scientists,” in response to headline-grabbing claims made by political figures around the world.

Familiar, reputable news outlets and credible expert-verified sources still remain the best places to find reliable facts.

“If you need information, obviously check your public health website first, but if you’re looking for general information about what’s going on I wouldn’t hesitate to go to your local media sources… Honest, fact-based news is more important than ever,” she concluded.

The B.C. Centre for Disease Control offers valuable COVID-19 information, as does the Provincial Government’s website.

Source: https://www.mybulkleylakesnow.com/41070/how-to-spot-fake-news-and-misinformation-in-the-era-of-covid-19/

Mota Ventures $MOTA.ca Reports Interim Record of 14,388 New Nature’s Exclusive Customers for April. Success Supports Launch of CBD Hand Sanitizer $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 9:27 AM on Monday, April 27th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png
  • MOTA VENTURES REPORTS INTERIM RECORD OF 14,388 NEW NATURE’S EXCLUSIVE CUSTOMERS FOR APRIL. SUCCESS SUPPORTS LAUNCH OF CBD HAND SANITIZER

Mota Ventures Corp. had an interim record number of new customer acquisitions for the month of April, for the period April 1 to April 23. Specifically, a total of 14,388 new customers were acquired for the Nature’s Exclusive brand. This interim new customer acquisition record will be updated with the final results for the complete month of April.

In addition to the record customer acquisition number, the Company is pleased to report that each new customer spent an average of $US 151.96. Finally, the record number included 1,748 new customers that purchased products in the immune support category.

SUCCESSFUL ONLINE CUSTOMER ACQUISITION STRATEGY SUPPORTS LAUNCH OF CBD BASED HAND SANITIZER

The interim record results demonstrate the strength and ability of the Company's online acquisition strategy to capitalize on the strong demand for natural health solutions. As a result, the Company will be launching a hand sanitizer product containing CBD through its Nature's Exclusive brand on May 1, 2020. The Nature's Exclusive CBD hand sanitizer will contain 70% ethyl alcohol as its active ingredient, as well as, CBD isolate and Vitamin E, and will initially be offered only to consumers in the United States.

In order to differentiate the Company's hand sanitizer offering within this crowded space, Mota has formulated a product that is specifically designed for its target consumers by combining the antimicrobial properties of ethyl alcohol with the benefits of CBD. This ability to formulate and innovate new products of this caliber is a direct result of the Company's strong supply chain, which has continued to operate uninterrupted despite the recent worldwide turmoil.

"I am very pleased with the continued strength of our new customer acquisition month-to-date as demand remains strong for our CBD and immune products. We anticipate similar demand for our new CBD Hand Sanitizer product due to the limited availability of sanitizer through current retail and eCommerce channels. This product offering will allow us to reach a new client base, while generating significant gross margin and attracting clients to our other product lines" stated Ryan Hoggan, CEO of the Company.

The Company will be hosting an investor conference call at 2:15pm PST on Monday, April 27, 2020 with Mota Ventures management, Ryan Hoggan, CEO and Joel Shacker, President. The Company will be accepting questions from investors at the end of the call.

Conference details:

Canada/USA TF: 1-800-319-4610International Toll: +1-604-638-5340Germany TF: 0800-180-1954Callers should dial in 5 – 10 min prior to the scheduled start time and simply ask to join the call.

Conference replay

Canada/USA TF: 1-800-319-6413International Toll: +1-604-638-9010Replay Access Code: 4481

This News Release is available on the company's CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature's Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

Empower Clinics $CBDT.ca Commences Corona Virus #Covid19 Antibody Testing and Establishes National Rollout Plan and Signs Supply Agreements for Rapid Covid-19 $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:18 AM on Monday, April 27th, 2020
  • Empower is utilizing clinic operations and tele-medicine to provide COVID-19 antibody testing to patients and consumers,
  • Establishes a four-phase nationwide rollout of Rapid COVID-19 testing and signs new COVID-19 test supply agreements

VANCOUVER, BC / April 27, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company”), a vertically integrated life sciences company is pleased to announce it has commenced COVID-19 antibody testing in its Sun Valley Health clinics in Phoenix, AZ using a blood draw test by clinic phlebotomists that are sent to an COVID-19 FDA approved laboratory partner. The laboratory submitted its request for FDA approval on March 16, 2020 under the Emergency Use Authorization (EUA).

“The Company has established a four-phase national COVID-19 testing program utilizing Rapid COVID-19 test kits”, said Steven McAuley, Chairman & CEO of Empower.

Phase One Testing in-clinics in Arizona, utilizing a patient blood draw by clinic phlebotomists, then samples are sent to our laboratory test partner for analysis, with test results expected within 48 hours.

Phase Two Offering a Rapid COVID-19 antibody test with results in 1-15 minutes. The service will be offered in-clinics using a drive-up service, conducted by Company clinic staff. In addition, an outbound door-step service, to support a variety of consumer, patient and community needs will be offered using certified mobile technicians. The Company anticipates phase two services will commence in May 2020.

Phase Three Business Employee Testing (BET) programs, offering Rapid COVID-19 testing to businesses on a one-time basis, repeat basis and/or subscription basis, to assist businesses to get back to work safely, will be offered. The Company anticipates phase three services will commence in May 2020.

Phase Four U.S. nationwide roll-out, offering all phases of Company services, that can be accessed online at Company websites and call centers, to purchase Rapid COVID-19 test kits. The Company anticipates phase four services to commence in Q3 2020.

Steven McAuley further states, “Our team are ready to meet the crisis head on, and we have ensured that the test processes and the test kits we use, are approved in the United States under the Emergency Use Authorization (EUA), as defined by the U.S. Food and Drug Administration (FDA).”

The Company has secured test kit supply agreements with two suppliers, NanoID Technologies Pty Ltd., that supply Zhuhai Livzon Diagnostics Inc. Rapid test kits, who made their test kit submission to the FDA on April 16th, 2020, and Emunah Trust, LLC, that supply Hangzhou TestSea Biotechnology Co., Ltd., Rapid test kits, who made their Rapid COVID-19 test kit submission to the FDA on April 16th, 2020.

CNN’s Dr. Sanjay Gupta explains what the science behind that testing means. Source: CNN

https://www.cnn.com/videos/health/2020/04/10/antibody-tests-fauci-week-or-so-gupta-dnt-lead-vpx.cnn

The World Health Organization, Director-General Dr. Tedros Adhanom Ghebreyesus has said, “Make no mistake: we have a long way to go. This virus will be with us for a long time. He has further stated, “We have a simple message for all counties: test, test, test.”

ABOUT EMPOWER

Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company now offers COVID-19 testing options and physician- based consultations, to address COVID-19 concerns.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

Chairman & CEO

[email protected]

604-789-2146

Investors: Dustin Klein

SVP, Business Development

720-352-1398

[email protected]

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four as noted above, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Steven J. McAuley
Chief Executive Officer
EMPOWER | www.empowerclinics.com
(604) 789-2146 | @stevenmcauley
[email protected]

Mota Ventures $MOTA.ca Reports Interim Record of 14,388 New Nature’s Exclusive Customers for April. Success Supports Launch of CBD Hand Sanitizer $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 2:28 PM on Saturday, April 25th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / April 25, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) is pleased to announce an interim record number of new customer acquisitions for the month of April, for the period April 1st – 23rd. Specifically, a total of 14,388 new customers were acquired for the Nature’s Exclusive brand. This interim new customer acquisition record will be updated with the final results for the complete month of April.

In addition to the record customer acquisition number, the Company is pleased to report that each new customer spent an average of $US 151.96. Finally, the record number included 1,748 new customers that purchased products in the immune support category.

SUCCESSFUL ONLINE CUSTOMER ACQUISITION STRATEGY SUPPORTS LAUNCH OF CBD BASED HAND SANITIZER

The interim record results demonstrate the strength and ability of the Company’s online acquisition strategy to capitalize on the strong demand for natural health solutions. As a result, the Company will be launching a hand sanitizer product containing CBD through its Nature’s Exclusive brand on May 1, 2020. The Nature’s Exclusive CBD hand sanitizer will contain 70% ethyl alcohol as its active ingredient, as well as, CBD isolate and Vitamin E, and will initially be offered only to consumers in the United States.

In order to differentiate the Company’s hand sanitizer offering within this crowded space, Mota has formulated a product that is specifically designed for its target consumers by combining the antimicrobial properties of ethyl alcohol with the benefits of CBD. This ability to formulate and innovate new products of this caliber is a direct result of the Company’s strong supply chain, which has continued to operate uninterrupted despite the recent worldwide turmoil.

“I am very pleased with the continued strength of our new customer acquisition month-to-date as demand remains strong for our CBD and immune products. We anticipate similar demand for our new CBD Hand Sanitizer product due to the limited availability of sanitizer through current retail and eCommerce channels. This product offering will allow us to reach a new client base, while generating significant gross margin and attracting clients to our other product lines” stated Ryan Hoggan, CEO of the Company.

The Company will be hosting an investor conference call at 2:15pm PST on Monday, April 27, 2020 with Mota Ventures management, Ryan Hoggan, CEO and Joel Shacker, President. The Company will be accepting questions from investors at the end of the call.

Conference details:

Canada/USA TF: 1-800-319-4610
International Toll: +1-604-638-5340
Germany TF: 0800-180-1954
Callers should dial in 5 – 10 min prior to the scheduled start time and simply ask to join the call.

Conference replay

Canada/USA TF: 1-800-319-6413
International Toll: +1-604-638-9010
Replay Access Code: 4481

This News Release is available on the company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact the President of the Company, Joel Shacker, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Even a #coronavirus crisis can’t puncture #palladium prices – SPONSOR: New Age Metals $NAM.ca $WG.ca $XTM.ca $WM.ca $PDL.ca $GLEN #PGM

Posted by AGORACOM-JC at 5:57 PM on Friday, April 24th, 2020

SPONSOR: New Age Metals Inc. The company owns one of North America’s largest primary platinum group metals deposits in Sudbury, Canada. The company has an updated NI 43-101 Mineral Resource Estimate of 2,867,000 PdEq Measured and Indicated Ounces, with an additional 1,059,000 PdEq Ounces Inferred. Learn More.

Even a coronavirus crisis can’t puncture palladium prices

  • “The palladium market is still in a deficit,” said INTL FCStone analyst Rhona O’Connell, and demand should revive as the global economy recovers.

By Peter Hobson and Harshith Aranya

Analysts and traders have raised their forecasts for palladium prices, predicting the metal will remain undersupplied even as the coronavirus outbreak hammers auto makers, reducing demand, a Reuters poll showed on Monday.

The sister metals are used mainly in engine exhausts to reduce harmful emissions, though platinum is also used by jewellers.

Prices have whipsawed as virus containment measures shuttered car plants, spooked markets and disrupted supply routes, particularly from top producer South Africa.

Palladium surged to a record high of $2,875.50 an ounce in February, plunged to below $1,500 in March, then rebounded to around $2,200.

Prices will average $2,100 an ounce this year and $2,150 in 2021, according to the median result from a poll of 24 analysts and traders conducted this month.

A similar poll in January forecast averages of $2,000 this year and $1,700 in 2021.

“The palladium market is still in a deficit,” said INTL FCStone analyst Rhona O’Connell, and demand should revive as the global economy recovers.

“But the effervescence of the past few years” – prices surged more than six-fold between 2016 and 2020 – “is in all probability behind us,” she said.

The roughly 10.5-million ounce a year palladium market will see a deficit of 500,000 ounces this year, said Robin Bhar, an independent analyst.

Refinitiv GFMS predicted a 883,000-ounce shortfall, while Capital Economics said it expected a surplus of 300,000 ounces.

Palladium has benefited in recent years from a tightening of emissions standards that require auto makers to use more metal per vehicle. Auto makers account for around 80% of palladium use.

By contrast, platinum is used mainly in diesel vehicles that have fallen in popularity since 2015, when Volkswagen was found to have cheated in emissions tests, and its use in jewellery has decreased.

Platinum prices plummeted in March to $558, the lowest since 2002, before pulling back to around $770.

The poll predicted platinum would average $836 an ounce in 2020 and $945 in 2021 ? a sharp downward revision from forecasts of $948 and $1,013 in the poll three months ago.

(Graphic: Platinum and palladium prices IMAGE link: https://fingfx.thomsonreuters.com/gfx/ce/nmovaabdvab/PGM%20Q2%20POLL.JPG)

Weaker economic growth because of measures to contain the novel coronavirus is likely to lead to lower consumption by auto makers, jewellers and other industrial users, such as glass makers.

“The scale of the demand-side destruction, along with the negative long-term chart set-up, suggests that downside price risks remain,” James Moore at Fastmarkets said.

Demand should gradually recover, driven in part by auto makers replacing some palladium with cheaper platinum, Saida Litosh at Refinitiv GFMS said.

Yet she still predicted surpluses in the roughly 8-million ounce a year market of 557,000 ounces this year and 670,000 ounces in 2021.

Source: https://www.marketscreener.com/PALLADIUM-89084/news/Even-a-coronavirus-crisis-can-t-puncture-palladium-prices-30445670/